Symbols / ACAD Stock $21.96 -0.68% ACADIA Pharmaceuticals Inc.

Healthcare • Biotechnology • United States • NMS
ACAD (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO Ms. Catherine E. Owen Adams
Exch · Country NMS · United States
Market Cap 3.74B
Enterprise Value 2.98B
Income 391.00M
Sales 1.07B
FCF (ttm) -54.82M
Book/sh 7.21
Cash/sh 4.81
Employees 796
Insider 10d —
IPO May 27, 2004
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E 9.55
Forward P/E 23.05
PEG 50.86
P/S 3.49
P/B 3.05
P/C —
EV/EBITDA 25.53
EV/Sales 2.78
Quick Ratio 3.49
Current Ratio 3.83
Debt/Eq 4.25
LT Debt/Eq —
EPS (ttm) 2.30
EPS next Y 0.95
EPS Growth 86.20%
Revenue Growth 9.40%
EPS Gr Q/Q 90.30%
Rev Gr Q/Q —
Earnings (next) 2026-05-06
Earnings (prior) 2026-02-25
ROA 4.76%
ROE 39.89%
ROIC —
Gross Margin 61.01%
Oper. Margin 6.12%
Profit Margin 36.49%
Shs Outstand 170.49M
Shs Float 126.61M
Insider Own 0.57%
Instit Own 99.86%
Short Float 10.04%
Short Ratio 5.87
Short Interest 10.98M
52W High 28.35
vs 52W High -22.54%
52W Low 14.18
vs 52W Low 54.87%
Beta 0.83
Impl. Vol. 0.20%
Rel Volume 0.48
Avg Volume 1.82M
Volume 868.16K
Target (mean) $31.70
Tgt Median $32.50
Tgt Low $17.00
Tgt High $45.00
# Analysts 20
Recom Buy
Prev Close $22.11
Price $21.96
Change -0.68%
About

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for neurological and rare disease in North America. The company offers NUPLAZID (pimavanserin), a selective serotonin inverse agonist/antagonist for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 to treat the symptoms of Rett syndrome by reducing neuroinflammation and supporting synaptic function. It also develops remlifanserin, which is in phase 2 clinical trial for the treatment of alzheimer's disease psychosis and lewy body dementia psychosis; ACP-211, which is in phase 2 clinical trial to treat major depressive disorder; ACP-711, which is in phase I clinical trial for the treatment of essential tremor; and ACP-271, a GPR88 agonist for the treatment of tardive dyskinesia and huntington's disease and is in phase I trial. In addition, the company develops ACP-2591, a cGP analogue which is in Phase 1 clinical trial to treat rett syndrome and fragile X syndrome; and STOKE Antisense Oligonucleotide Program, which is in discovery program for SYNGAP1 syndrome. It has a license agreement with Neuren Pharmaceuticals Limited to trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop, and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$31.70
Mean price target
2. Current target
$21.96
Latest analyst target
3. DCF / Fair value
$-5.79
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$21.96
Low
$17.00
High
$45.00
Mean
$31.70

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-03-25 up B of A Securities Neutral → Buy $29
2026-03-04 main JP Morgan Overweight → Overweight $34
2026-02-26 main TD Cowen Buy → Buy $37
2026-02-26 main RBC Capital Outperform → Outperform $30
2026-02-26 main Citizens Market Outperform → Market Outperform $35
2026-02-26 main Stifel Hold → Hold $24
2026-02-24 init Wolfe Research — → Outperform $33
2026-02-23 up Mizuho Neutral → Outperform $35
2026-02-06 main Oppenheimer Perform → Perform $23
2026-02-03 main RBC Capital Outperform → Outperform $31
2026-02-03 reit Citizens Market Outperform → Market Outperform $34
2026-02-03 reit HC Wainwright & Co. Buy → Buy $37
2026-01-06 main Citigroup Buy → Buy $36
2026-01-06 main UBS Buy → Buy $40
2025-12-15 main HC Wainwright & Co. Buy → Buy $37
2025-12-11 main Stifel Hold → Hold $25
2025-12-02 main Mizuho Neutral → Neutral $29
2025-11-17 main JP Morgan Overweight → Overweight $31
2025-11-06 main RBC Capital Outperform → Outperform $32
2025-11-06 main Needham Buy → Buy $29
News
RSS: Latest ACAD news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-04-07 KIHARA JAMES Officer — 1,030 $22.20 $22,866
2026-04-07 SCHNEYER MARK C. Chief Financial Officer — 2,709 $22.20 $60,140
2026-04-02 KIHARA JAMES Officer — 2,010 — —
2026-04-02 SCHNEYER MARK C. Chief Financial Officer — 5,276 — —
2026-03-26 KIHARA JAMES Officer — 1,942 $21.47 $41,895
2026-03-26 SCHNEYER MARK C. Chief Financial Officer — 7,385 $21.47 $159,136
2026-03-25 KIHARA JAMES Officer — 3,769 — —
2026-03-25 ADAMS CATHERINE OWEN Chief Executive Officer — 11,641 $21.47 $249,932
2026-03-25 RHODES JENNIFER J. Officer — 3,844 $21.47 $82,531
2026-03-25 THOMPSON ELIZABETH H.Z. Officer — 3,435 $21.47 $73,749
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
1,071.51
+11.87%
957.80
+31.85%
726.44
+40.45%
517.24
Operating Revenue
1,071.51
+11.87%
957.80
+31.85%
726.44
+40.45%
517.24
Cost Of Revenue
89.00
+8.75%
81.84
+96.55%
41.64
+309.58%
10.17
Reconciled Cost Of Revenue
89.00
+8.75%
81.84
+96.55%
41.64
+309.58%
10.17
Gross Profit
982.51
+12.16%
875.96
+27.91%
684.80
+35.05%
507.07
Operating Expense
877.70
+10.87%
791.68
+4.42%
758.18
+3.77%
730.66
Research And Development
328.80
+8.43%
303.25
-13.76%
351.62
-2.75%
361.57
Selling General And Administration
548.89
+12.38%
488.43
+20.14%
406.56
+10.15%
369.09
General And Administrative Expense
—
—
—
—
Other Gand A
—
—
—
—
Total Expenses
966.69
+10.67%
873.52
+9.21%
799.82
+7.96%
740.83
Operating Income
104.81
+24.36%
84.28
+214.85%
-73.38
+67.18%
-223.60
Total Operating Income As Reported
104.81
-54.59%
230.79
+414.52%
-73.38
+67.18%
-223.60
EBITDA
116.57
+16.38%
100.16
+247.67%
-67.83
+69.39%
-221.57
Normalized EBITDA
116.57
+351.49%
-46.35
+31.66%
-67.83
+69.39%
-221.57
Reconciled Depreciation
11.76
-25.96%
15.88
+186.08%
5.55
+174.04%
2.03
EBIT
104.81
+24.36%
84.28
+214.85%
-73.38
+67.18%
-223.60
Total Unusual Items
0.00
-100.00%
146.51
0.00
0.00
Total Unusual Items Excluding Goodwill
0.00
-100.00%
146.51
0.00
0.00
Special Income Charges
0.00
-100.00%
146.51
0.00
0.00
Net Income
391.00
+72.66%
226.45
+469.50%
-61.29
+71.62%
-215.97
Pretax Income
138.90
-46.18%
258.07
+605.67%
-51.04
+76.09%
-213.44
Net Non Operating Interest Income Expense
31.72
+24.61%
25.46
+47.72%
17.23
+160.73%
6.61
Net Interest Income
31.72
+24.61%
25.46
+47.72%
17.23
+160.73%
6.61
Interest Income Non Operating
31.72
+24.61%
25.46
+47.72%
17.23
+160.73%
6.61
Interest Income
31.72
+24.61%
25.46
+47.72%
17.23
+160.73%
6.61
Other Income Expense
2.37
-98.40%
148.34
+2803.46%
5.11
+44.24%
3.54
Other Non Operating Income Expenses
2.37
+30.06%
1.82
-64.32%
5.11
+44.24%
3.54
Tax Provision
-252.10
-897.17%
31.62
+208.53%
10.25
+304.98%
2.53
Tax Rate For Calcs
0.00
+71.38%
0.00
-41.65%
0.00
+0.00%
0.00
Tax Effect Of Unusual Items
0.00
-100.00%
17.95
0.00
0.00
Net Income Including Noncontrolling Interests
391.00
+72.66%
226.45
+469.50%
-61.29
+71.62%
-215.97
Net Income From Continuing Operation Net Minority Interest
391.00
+72.66%
226.45
+469.50%
-61.29
+71.62%
-215.97
Net Income From Continuing And Discontinued Operation
391.00
+72.66%
226.45
+469.50%
-61.29
+71.62%
-215.97
Net Income Continuous Operations
391.00
+72.66%
226.45
+469.50%
-61.29
+71.62%
-215.97
Normalized Income
391.00
+299.43%
97.89
+259.73%
-61.29
+71.62%
-215.97
Net Income Common Stockholders
391.00
+72.66%
226.45
+469.50%
-61.29
+71.62%
-215.97
Diluted EPS
2.30
+69.12%
1.36
+467.57%
-0.37
+72.39%
-1.34
Basic EPS
2.32
+69.34%
1.37
+470.27%
-0.37
+72.39%
-1.34
Basic Average Shares
168.36
+1.59%
165.72
+1.16%
163.82
+1.32%
161.68
Diluted Average Shares
169.92
+2.14%
166.36
+1.55%
163.82
+1.32%
161.68
Diluted NI Availto Com Stockholders
391.00
+72.66%
226.45
+469.50%
-61.29
+71.62%
-215.97
Gain On Sale Of PPE
0.00
-100.00%
146.51
0.00
0.00
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Assets
1,564.19
+31.69%
1,187.76
+58.59%
748.96
+27.41%
587.81
Current Assets
1,062.11
+13.19%
938.32
+52.29%
616.12
+21.30%
507.94
Cash Cash Equivalents And Short Term Investments
819.69
+8.43%
755.99
+72.26%
438.87
+5.29%
416.82
Cash And Cash Equivalents
177.69
-44.40%
319.59
+69.40%
188.66
+64.27%
114.85
Other Short Term Investments
641.99
+47.11%
436.40
+74.42%
250.21
-17.14%
301.98
Receivables
148.23
+41.58%
104.69
+2.29%
102.35
+62.25%
63.08
Accounts Receivable
121.46
+23.01%
98.74
+0.48%
98.27
+58.00%
62.20
Accrued Interest Receivable
26.77
+349.53%
5.96
+45.87%
4.08
+361.36%
0.89
Inventory
34.67
+57.96%
21.95
-38.72%
35.82
+439.77%
6.64
Raw Materials
—
—
—
0.28
Work In Process
—
—
—
4.43
Finished Goods
—
—
—
1.93
Prepaid Assets
59.53
+6.91%
55.68
+42.44%
39.09
+82.69%
21.40
Total Non Current Assets
502.08
+101.29%
249.44
+87.79%
132.83
+66.30%
79.88
Net PPE
54.87
+8.03%
50.79
-10.06%
56.47
-8.32%
61.59
Gross PPE
64.35
+5.48%
61.00
-7.60%
66.02
-5.26%
69.69
Accumulated Depreciation
-9.48
+7.17%
-10.22
-6.92%
-9.56
-18.02%
-8.10
Properties
0.00
0.00
0.00
0.00
Machinery Furniture Equipment
9.09
-10.57%
10.16
-2.49%
10.42
+0.00%
10.42
Construction In Progress
3.26
+523.71%
0.52
0.00
—
Other Properties
47.35
+1.68%
46.57
-10.19%
51.85
-6.69%
55.57
Leases
4.64
+23.97%
3.75
+0.00%
3.75
+1.35%
3.70
Goodwill And Other Intangible Assets
108.89
-9.09%
119.78
+82.90%
65.49
0.00
Non Current Deferred Assets
249.88
0.00
—
—
Non Current Deferred Taxes Assets
249.88
0.00
—
—
Other Non Current Assets
88.44
+12.14%
78.87
+625.31%
10.87
-40.52%
18.28
Total Liabilities Net Minority Interest
336.81
-25.97%
454.96
+43.43%
317.20
+69.27%
187.40
Current Liabilities
277.11
-29.82%
394.87
+55.31%
254.25
+102.38%
125.63
Payables And Accrued Expenses
219.90
-36.88%
348.36
+72.34%
202.13
+128.91%
88.30
Payables
11.21
-60.27%
28.21
+47.63%
19.11
+45.60%
13.12
Accounts Payable
10.90
-32.66%
16.19
-7.70%
17.54
+37.64%
12.75
Current Accrued Expenses
208.69
-34.81%
320.15
+74.92%
183.02
+143.45%
75.18
Pensionand Other Post Retirement Benefit Plans Current
45.58
+24.70%
36.55
-14.44%
42.72
+52.44%
28.02
Total Tax Payable
0.30
-97.47%
12.02
+668.29%
1.56
+314.85%
0.38
Current Debt And Capital Lease Obligation
11.63
+16.82%
9.96
+5.88%
9.40
+1.07%
9.30
Current Capital Lease Obligation
11.63
+16.82%
9.96
+5.88%
9.40
+1.07%
9.30
Total Non Current Liabilities Net Minority Interest
59.69
-0.67%
60.09
-4.53%
62.95
+1.91%
61.77
Long Term Debt And Capital Lease Obligation
40.55
-3.53%
42.04
-12.06%
47.80
-9.29%
52.70
Long Term Capital Lease Obligation
40.55
-3.53%
42.04
-12.06%
47.80
-9.29%
52.70
Other Non Current Liabilities
19.14
+5.99%
18.06
+19.21%
15.15
+66.93%
9.07
Stockholders Equity
1,227.39
+67.49%
732.79
+69.72%
431.75
+7.83%
400.41
Common Stock Equity
1,227.39
+67.49%
732.79
+69.72%
431.75
+7.83%
400.41
Capital Stock
0.02
+0.00%
0.02
+0.00%
0.02
+0.00%
0.02
Common Stock
0.02
+0.00%
0.02
+0.00%
0.02
+0.00%
0.02
Preferred Stock
0.00
0.00
0.00
0.00
Share Issued
170.31
+2.16%
166.71
+1.25%
164.65
+1.60%
162.06
Ordinary Shares Number
170.31
+2.16%
166.71
+1.25%
164.65
+1.60%
162.06
Additional Paid In Capital
3,039.32
+3.49%
2,936.87
+2.60%
2,862.55
+3.31%
2,770.92
Retained Earnings
-1,813.39
+17.74%
-2,204.39
+9.32%
-2,430.84
-2.59%
-2,369.55
Gains Losses Not Affecting Retained Earnings
1.45
+394.86%
0.29
+1116.67%
0.02
+102.46%
-0.97
Other Equity Adjustments
1.45
+394.86%
0.29
+1116.67%
0.02
+102.46%
-0.97
Total Equity Gross Minority Interest
1,227.39
+67.49%
732.79
+69.72%
431.75
+7.83%
400.41
Total Capitalization
1,227.39
+67.49%
732.79
+69.72%
431.75
+7.83%
400.41
Working Capital
785.00
+44.45%
543.45
+50.18%
361.87
-5.35%
382.31
Invested Capital
1,227.39
+67.49%
732.79
+69.72%
431.75
+7.83%
400.41
Total Debt
52.19
+0.37%
51.99
-9.11%
57.20
-7.73%
62.00
Capital Lease Obligations
52.19
+0.37%
51.99
-9.11%
57.20
-7.73%
62.00
Net Tangible Assets
1,118.50
+82.46%
613.01
+67.37%
366.26
-8.53%
400.41
Tangible Book Value
1,118.50
+82.46%
613.01
+67.37%
366.26
-8.53%
400.41
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
109.84
-30.36%
157.72
+844.31%
16.70
+114.65%
-114.03
Cash Flow From Continuing Operating Activities
109.84
-30.36%
157.72
+844.31%
16.70
+114.65%
-114.03
Net Income From Continuing Operations
391.00
+72.66%
226.45
+469.50%
-61.29
+71.62%
-215.97
Depreciation Amortization Depletion
11.76
-25.96%
15.88
+186.08%
5.55
+174.04%
2.03
Depreciation
0.87
-5.33%
0.92
-36.94%
1.46
-27.99%
2.03
Amortization Cash Flow
10.89
-27.23%
14.96
+265.58%
4.09
0.00
Depreciation And Amortization
11.76
-25.96%
15.88
+186.08%
5.55
+174.04%
2.03
Amortization Of Intangibles
10.89
-27.23%
14.96
+265.58%
4.09
0.00
Other Non Cash Items
-249.88
—
—
—
Stock Based Compensation
52.13
-22.24%
67.05
+0.95%
66.42
-2.61%
68.20
Operating Gains Losses
—
-146.51
-3095.53%
-4.58
-29.45%
-3.54
Gain Loss On Investment Securities
—
—
-4.58
-29.45%
-3.54
Change In Working Capital
-89.76
-2260.19%
4.16
-77.09%
18.13
-52.27%
37.99
Change In Receivables
-43.54
-1756.55%
-2.35
+94.03%
-39.27
-1834.54%
2.26
Changes In Account Receivables
-22.72
-4713.14%
-0.47
+98.69%
-36.07
-1761.54%
2.17
Change In Inventory
-18.20
+63.28%
-49.55
-72.00%
-28.81
-1292.88%
2.42
Change In Payables And Accrued Expense
-24.55
-135.22%
69.71
-28.84%
97.97
+224.65%
30.18
Change In Accrued Expense
-19.27
-127.11%
71.06
-23.73%
93.17
+283.32%
24.31
Change In Payable
-5.29
-291.49%
-1.35
-128.16%
4.80
-18.28%
5.87
Change In Account Payable
-5.29
-291.49%
-1.35
-128.16%
4.80
-18.28%
5.87
Change In Other Current Assets
5.81
-23.73%
7.62
+32.83%
5.74
-12.00%
6.52
Change In Other Current Liabilities
-5.43
-15.91%
-4.69
-2432.84%
0.20
+103.42%
-5.88
Investing Cash Flow
-302.56
-890.78%
-30.54
-195.44%
32.00
-56.31%
73.24
Cash Flow From Continuing Investing Activities
-302.56
-890.78%
-30.54
-195.44%
32.00
-56.31%
73.24
Net PPE Purchase And Sale
-4.69
-796.75%
-0.52
-946.00%
-0.05
0.00
Purchase Of PPE
-4.69
-796.75%
-0.52
-946.00%
-0.05
0.00
Capital Expenditure
-4.69
-796.75%
-0.52
-946.00%
-0.05
—
Net Investment Purchase And Sale
-199.04
-12.75%
-176.53
-345.02%
72.05
-1.63%
73.24
Purchase Of Investment
-692.57
-37.12%
-505.10
-36.52%
-369.99
-1.88%
-363.17
Sale Of Investment
493.53
+50.21%
328.56
-25.67%
442.03
+1.29%
436.42
Net Business Purchase And Sale
-98.84
0.00
+100.00%
-40.00
—
Purchase Of Business
-98.84
0.00
+100.00%
-40.00
—
Net Intangibles Purchase And Sale
—
0.00
+100.00%
-40.00
0.00
Net Other Investing Changes
—
146.51
—
—
Financing Cash Flow
49.88
+628.75%
6.84
-72.76%
25.13
+206.49%
8.20
Cash Flow From Continuing Financing Activities
49.88
+628.75%
6.84
-72.76%
25.13
+206.49%
8.20
Net Common Stock Issuance
49.88
+628.75%
6.84
-72.76%
25.13
+206.49%
8.20
Changes In Cash
-142.84
-206.58%
134.03
+81.54%
73.83
+326.50%
-32.59
Effect Of Exchange Rate Changes
0.03
+127.66%
-0.09
-422.22%
-0.02
-400.00%
0.01
Beginning Cash Position
328.36
+68.89%
194.43
+61.20%
120.62
-21.27%
153.21
End Cash Position
185.54
-43.49%
328.36
+68.89%
194.43
+61.20%
120.62
Free Cash Flow
105.15
-33.11%
157.20
+844.01%
16.65
+114.60%
-114.03
Income Tax Paid Supplemental Data
25.17
+28.94%
19.52
+233.69%
5.85
+167.12%
2.19
Amortization Of Securities
-5.42
+41.70%
-9.30
-23.51%
-7.53
-175.33%
-2.74
Common Stock Issuance
49.88
+628.75%
6.84
-72.76%
25.13
+206.49%
8.20
Issuance Of Capital Stock
49.88
+628.75%
6.84
-72.76%
25.13
+206.49%
8.20
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category